Home/Recalls/CANADA-76226
Health CanadaGeneral Alert

M-Eslon (morphine sulfate) ER capsules: One lot recalled as some bottles labelle...

Published: September 27, 2024Recall ID: 76226Category: generalCountry: Canada

Reason for Recall / Hazard

Product safety

Product Description & Identification

Check your M-Eslon (morphine sulfate) medication bottle or package. If your prescription is for 30 mg, the capsules should be pink and clear. If it contains 60 mg capsules (orange and clear), or if you are unsure, do not take these capsules and contact your pharmacy immediately. Your pharmacist will check the capsules and provide you with a replacement if needed. Return the affected product to your pharmacy for proper disposal.Call 911 immediately and seek immediate medical attention if you or someone you are caring for is experiencing an overdose (e.g., slow breathing, drowsiness, or difficulties waking up).If an overdose is suspected, administer naloxone nasal spray or injection without delay. Give a repeat dose after 2 to 3 minutes if the person has not woken up or their breathing has not improved.Contact your health care professional if you have taken the wrong dose of your medication and have any health concerns.If you have questions about this recall contact Ethypharm Inc. by calling 1-855-694-0151, or by emailing customerservice@valeopharma.com.Report any health product-related side effectsor complaints to Health Canada.Additional information for health professionals:Health care professionals, such as pharmacists, should check bottles labelled as M-Eslon (morphine sulfate) 30 mg extended release (ER) capsules before dispensing to make sure they do not contain M-Eslon 60 mg ER capsules. Report any unusual bottles or other issues to the company and to Health Canada.

Affected Products

M-Eslon (morphine sulfate) bottles labelled to contain 30 mg extended-release capsules may contain 60 mg extended-release capsules

Additional Source Details

FieldValue
N I D76226
U R Lhttps://recalls-rappels.canada.ca/en/alert-recall/m-eslon-morphine-sulfate-er-capsules-one-lot-recalled-some-bottles-labelled-m-eslon-30
IssueProduct safety
TitleM-Eslon (morphine sulfate) ER capsules: One lot recalled as some bottles labelled as M-Eslon 30 mg may contain 60 mg capsules, which may pose an overdose risk
ProductM-Eslon (morphine sulfate) bottles labelled to contain 30 mg extended-release capsules may contain 60 mg extended-release capsules
Archived0
CategoryDrugs
Last updated2024-09-27
OrganizationCommunications and Public Affairs Branch
What you should doCheck your M-Eslon (morphine sulfate) medication bottle or package. If your prescription is for 30 mg, the capsules should be pink and clear. If it contains 60 mg capsules (orange and clear), or if you are unsure, do not take these capsules and contact your pharmacy immediately. Your pharmacist will check the capsules and provide you with a replacement if needed. Return the affected product to your pharmacy for proper disposal.Call 911 immediately and seek immediate medical attention if you or someone you are caring for is experiencing an overdose (e.g., slow breathing, drowsiness, or difficulties waking up).If an overdose is suspected, administer naloxone nasal spray or injection without delay. Give a repeat dose after 2 to 3 minutes if the person has not woken up or their breathing has not improved.Contact your health care professional if you have taken the wrong dose of your medication and have any health concerns.If you have questions about this recall contact Ethypharm Inc. by calling 1-855-694-0151, or by emailing customerservice@valeopharma.com.Report any health product-related side effectsor complaints to Health Canada.Additional information for health professionals:Health care professionals, such as pharmacists, should check bottles labelled as M-Eslon (morphine sulfate) 30 mg extended release (ER) capsules before dispensing to make sure they do not contain M-Eslon 60 mg ER capsules. Report any unusual bottles or other issues to the company and to Health Canada.

Overview

  • Recalling FirmCommunications and Public Affairs Branch
Official Agency Alert